FY2024 · ended Dec 31, 2024 · Revenue $5.11M, -12.2% YoY · Filed Apr 15, 2026
Petros Pharmaceuticals, Inc. (PTPI) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
$5.11M
-12.2% vs prior year
Net income
$1.91M
+113.4% vs prior year
Operating cash flow (TTM)
$-3.72M
+16.9% vs year-ago TTM
Free cash flow
$-2.63M
EPS
$-1.56
+98.1% vs prior year
Dividend per share
None
Shares outstanding
42.37M
-20.8% vs prior year
Net cash
$1.58M
FY 2024
Operating margin
-90.5%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PTPI (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1815903
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | $5.1M | $5.8M | $6.0M | $7.8M |
| Operating income | -$4.6M | -$4.6M | -$13.6M | -$19.9M | -$18.0M |
| Net income | $1.9M | -$14.3M | -$8.2M | -$20.0M | -$9.0M |
| Diluted EPS | -$1.56 | -$83.47 | -$6.35 | -$9.68 | -$8.25 |
| Operating cash flow | -$6.7M | -$2.6M | -$7.6M | -$12.8M | -$11.9M |
| Free cash flow | — | -$2.6M | — | — | — |
| Total assets | $5.2M | $10.6M | $33.8M | $32.4M | $67.4M |
| Total liabilities | $2.3M | $18.1M | $21.3M | $15.7M | $31.8M |
| Stockholders' equity | $2.9M | -$7.5M | $12.1M | $16.7M | $35.5M |
| Cash and investments | $5.1M | $1.7M | $13.3M | $9.4M | $23.8M |
| Total debt | — | $137,656 | $262,677 | $405,017 | $530,597 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Bankruptcy, Officer or director change
|
Sep 30, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 18, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 5, 2026 | Jun 5, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
| 10-K | Annual report | Apr 15, 2026 | Dec 31, 2025 |
All 257 Petros Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.